Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Argent Biopharma ( (AU:RGT) ) has provided an update.
Argent BioPharma has issued 1,000,000 fully paid ordinary shares and confirmed that these securities can be freely traded under the exemption provisions of section 708A(5) of the Corporations Act 2001. The company stated that the shares were issued without a prospectus, affirmed its compliance with applicable financial reporting and continuous disclosure obligations, and said there is no undisclosed information that investors would reasonably require to assess its financial position, prospects or the rights attached to the new shares.
This move supports Argent BioPharma’s capital structure while signalling adherence to Australian corporate governance and disclosure standards, potentially reinforcing investor confidence in its regulatory standing. By clarifying that the new shares qualify for on-sale without additional disclosure and that no material information has been withheld, the company reduces legal uncertainty for secondary trading and underpins liquidity for existing and new shareholders.
The most recent analyst rating on (AU:RGT) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.
More about Argent Biopharma
Argent BioPharma Ltd. (ASX: RGT) is a clinical-stage biopharmaceutical company developing nano-engineered medicines that modulate interactions between the nervous and immune systems. Its lead drug candidates, CannEpil for drug-resistant epilepsy and CimetrA for cytokine-driven inflammatory and autoimmune disorders, use proprietary delivery platforms aimed at enhancing penetration across the blood–brain and alveolar–capillary barriers. The company leverages EU-GMP manufacturing, late-stage clinical programs and a unified neuro-immune modulatory platform to address urgent unmet needs in central nervous system and systemic inflammatory diseases.
Average Trading Volume: 184,673
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$4.78M
See more data about RGT stock on TipRanks’ Stock Analysis page.